Cardioxyl has developed a nitroxyl (HNO) chemistry platform technology that serves as the foundation for the company's drug discovery efforts. The work of Cardioxyl's scientific founders at Johns Hopkins University and their colleagues originally elucidated the cardiovascular effects of nitroxyl, and propelled interest in this unique chemical space. Cardioxyl has since developed a formidable intellectual property portfolio and industry-leading nitroxyl chemistry, pharmacology, manufacturing and formulation expertise.
In extensive pre-clinical testing and in a Phase IIa human proof of concept study with Cardioxyl’s first-generation prodrug, HNO has been shown to produce a unique and very attractive hemodynamic profile. In addition to vasodilation, HNO acts directly on the heart via a unique mechanism to safely enhance both systolic and diastolic function. The novel combination of effects produced by Cardioxyl’s HNO prodrugs distinguishes them from other therapies used in the treatment of congestive heart failure and provides a strong rationale for continuing the development of this important new class of drugs.